Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed

BACKGROUND: There has been no previous study on the activity of gemcitabine in combination with oxaliplatin (GemOx) for castration-resistant prostate cancer (CRPC). METHODS: The GemOx was preclinically tested for cytotoxic activity in human prostate cancer cell lines. Clinically, patients with CRPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, J-L, Ahn, J-H, Choi, M K, Kim, Y, Hong, S-W, Lee, K-H, Jeong, I-G, Song, C, Hong, B-S, Hong, J H, Ahn, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021534/
https://www.ncbi.nlm.nih.gov/pubmed/24736579
http://dx.doi.org/10.1038/bjc.2014.204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021534/
https://www.ncbi.nlm.nih.gov/pubmed/24736579
http://dx.doi.org/10.1038/bjc.2014.204

Ejemplares similares